KNSA: Kiniksa Pharmaceuticals Ltd Price to Sales
The P/S business valuation on the GURU.Markets dynamic chart illustrates an ecosystem for treating rare cardiovascular pathologies, where the 4.90 value characterizes this level. Kiniksa Pharmaceuticals (KNSA) is developing therapies for immune failures through partnerships with biotech institutes. Strong patents in the inflammatory heart disease niche ensure high margins and a lack of direct market equivalents.
Analytical breakdowns for kiniksa.com (KNSA)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
- company profitability and valuation multiples indicators:
KNSA - Net Income|Expected Net Income Kiniksa Pharmaceuticals|KNSA - Price to Earnings Ratio|Price to Expected Earnings Ratio Kiniksa Pharmaceuticals Ltd|KNSA - PEG Multiple|Business Value to Operating Income Before Depreciation Kiniksa Corp|KNSA - Operating profit EBITDA|Net earnings per share (EPS TTM) Kiniksa|KNSA - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months kiniksa.com|KNSA - Earnings per share growth in current year|Expected earnings per share growth for next year Kiniksa Pharmaceuticals
- issuer revenue and sales details:
Fundamental company analysis:KNSA Kiniksa Pharmaceuticals, Ltd.
The monopoly status of Kiniksa Pharmaceuticals (KNSA) in the treatment of inflammatory diseases, secured by antibody patents, directly impacts the market valuation of its revenue. The current value of 4.90 reflects the ratio of market capitalization to sales volume, demonstrating how much investors are willing to pay per unit of revenue; the history of the price-to-sales multiple allows for an assessment of the balance between the asset's prestige and the risks of overvaluation.
Competitors of Kiniksa Pharmaceuticals
argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|Grifols - Market Capitalization-to-Revenue Ratio|ADPT (Adaptive Biotech) - P/S Multiple|Price-to-Revenue Ratio CLDX|P/S Multiple AUPH|Market Cap to Revenue biocryst.com BCRX|Vera Therapeutics - Market Cap to Revenue|Market Cap to Sales Volume DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV - P/S Multiple|ABCL: Price-to-Revenue Ratio|Tourmaline Bio, Inc. (TRML) - Price-to-Revenue Ratio|Price to Sales precigen.com (PGEN)|PHAR (pharming.com) - P/S Multiple|NKTR (Nektar Therapeutics Inc.) - Market Cap to Sales Volume|P/S Multiple UPB|ZBIO - Price to Sales|P/S Multiple IMNM (immunome.com)|Gossamer Bio, Inc. - Price-to-Revenue Ratio|KalVista Pharmaceuticals, Inc. - P/S Multiple|SEPN (Septerna) - Market Cap to Revenue Ratio|Pieris Corp (PVLA) - Price-to-Revenue Ratio|SVRA - Price-to-Revenue Coefficient|RIGL (rigel.com) - P/S Multiple|Market Cap to Revenue Ratio ANAB (AnaptysBio, Inc.)|P/S Multiple ATXS|enGene Holdings Inc (ENGN) - Price-to-Revenue Multiple|P/S Multiple RAPT (RAPT Therapeutics Inc.)|JBIO (Aerovate) - Price-to-Sales Ratio|ACRS: Market Cap to Revenue|KYTX - P/S Multiple|TLSA: P/S Multiple|Market Cap to Revenue Cabaletta Bio, Inc|Price-to-Revenue Ratio Ventyx Biosciences, Inc|THTX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue AVTX (Avalo Therapeutics, Inc)|Market Cap to Revenue Eledon Pharmaceuticals ELDN|Price-to-Revenue Ratio Agenus, Inc. AGEN|P/S Multiple Climb Bio Inc. CLYM|ZURA - Price-to-Revenue Ratio|Price-to-Sales Ratio ATYR|ADAG (Adagene Inc.) - Market Cap to Revenue|ImageneBio Inc (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Therapeutics|Market Cap to Revenue equilliumbio.com (EQ)|P/S Multiple CNTB|Price-to-Revenue Coefficient Immunic Therapeutics|P/S Multiple ATRA (Atara Biotherapeutics, Inc.)|IFRX - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Market Cap to Revenue Ratio|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Biotherapeutics plc|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|AKTX (Akari Therapeutics Plc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple
